Pfizer (NYSE:PFE) had its price objective lifted by Morgan Stanley from $36.00 to $42.00 in a research note issued to investors on Thursday, The Fly reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the stock. SVB Leerink boosted their price objective on shares of Pfizer from $39.00 to $42.00 and gave the company a market perform rating in a report on Wednesday. JPMorgan Chase & Co. cut their price target on Pfizer from $37.00 to $36.00 and set a neutral rating for the company in a research note on Monday, June 1st. TheStreet upgraded Pfizer from a c+ rating to a b rating in a research note on Monday, June 1st. Barclays cut their price objective on Pfizer from $37.00 to $35.00 in a research note on Monday, June 1st. Finally, Zacks Investment Research cut Pfizer from a buy rating to a hold rating and set a $40.00 target price on the stock. in a report on Monday, May 4th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $38.95.

Shares of NYSE:PFE traded down $0.26 on Thursday, reaching $38.48. The company’s stock had a trading volume of 27,042,691 shares, compared to its average volume of 32,108,124. Pfizer has a 52-week low of $27.88 and a 52-week high of $40.97. The company has a market cap of $213.75 billion, a P/E ratio of 15.27, a PEG ratio of 3.10 and a beta of 0.68. The company has a 50-day simple moving average of $34.75 and a 200 day simple moving average of $35.79. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.78 and a current ratio of 1.02.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.14. The company had revenue of $11.80 billion during the quarter, compared to analysts’ expectations of $11.55 billion. Pfizer had a net margin of 28.80% and a return on equity of 25.10%. The firm’s quarterly revenue was down 11.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.80 EPS. On average, equities research analysts forecast that Pfizer will post 2.9 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 31st will be given a $0.38 dividend. This represents a $1.52 annualized dividend and a yield of 3.95%. The ex-dividend date is Thursday, July 30th. Pfizer’s dividend payout ratio is currently 51.53%.

In other Pfizer news, SVP Jennifer B. Damico sold 2,181 shares of Pfizer stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $36.13, for a total value of $78,799.53. Following the completion of the transaction, the senior vice president now directly owns 7,542 shares of the company’s stock, valued at approximately $272,492.46. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.08% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp boosted its stake in shares of Pfizer by 0.3% in the 1st quarter. State Street Corp now owns 292,621,398 shares of the biopharmaceutical company’s stock valued at $9,551,162,000 after buying an additional 830,299 shares during the period. Capital World Investors grew its stake in shares of Pfizer by 19.1% during the first quarter. Capital World Investors now owns 224,808,113 shares of the biopharmaceutical company’s stock worth $7,337,737,000 after buying an additional 36,092,723 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Pfizer by 12.9% during the first quarter. Wellington Management Group LLP now owns 218,676,145 shares of the biopharmaceutical company’s stock worth $7,137,589,000 after buying an additional 24,950,461 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Pfizer by 1.0% during the first quarter. Geode Capital Management LLC now owns 89,953,885 shares of the biopharmaceutical company’s stock worth $2,931,423,000 after buying an additional 910,123 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its stake in shares of Pfizer by 30.9% in the first quarter. Nuveen Asset Management LLC now owns 40,753,427 shares of the biopharmaceutical company’s stock worth $1,330,192,000 after purchasing an additional 9,624,759 shares during the last quarter. Institutional investors and hedge funds own 70.20% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: What is an economic bubble?

The Fly

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.